Maxwell Biosciences is a preclinical stage drug platform company focusing on next-generation anti-infectives that mimic natural human antimicrobial peptides
Maxwell Biosciences is a preclinical stage drug platform company focusing on next-generation anti-infectives that mimic natural human antimicrobial peptides. Their CLAROMER™ drug discovery platform aims to develop patented low molecular weight drug candidates effective against a broad spectrum of pathogens, including SARS-CoV-2 and other viruses, bacteria, and fungi.